Intervention
Placebo for upadacitinib
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 3 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownA Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With UpadacitinibNCT03823378 · 2019-05-13
TERMINATEDA Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid ArthritisNCT03682705 · 2018-10-08
COMPLETEDA Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsNCT03086343 · 2017-05-09
COMPLETEDCommon conditions
Leading sponsors
Trial status mix
COMPLETED2
TERMINATED1
Phase mix
PHASE22
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.